טוען...
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
Idarucizumab is the first targeted antidote of dabigatran, a direct oral anticoagulant used for prevention and treatment of venous thromboembolism and prevention of stroke in atrial fibrillation. Idarucizumab is a humanized fragment of a monoclonal antibody, which binds dabigatran reversibly with hi...
שמור ב:
| הוצא לאור ב: | Drug Des Devel Ther |
|---|---|
| מחבר ראשי: | |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4876800/ https://ncbi.nlm.nih.gov/pubmed/27274201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S94167 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|